Search

The article offers information on the U.S. Food & Drug Administration (FDA) approval of canakinumab (Ilaris) for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine or repeated corticosteroids. It discusses that this humanized anti–interleukin-1 beta monoclonal antibody is the first biologic approved in the U.S. for this indication; and also addressing an unmet need in patients with gout flares.

The article offers insights on the diagnosis and treatment of dry eye. According to Doctor Pierre-Jean Pisella, dry eye was given a new definition by the Tear Film and Ocular Surface Society after recognizing that the condition always has ocular surface inflammation. The pathogenesis and progression of dry eye and the existing diagnostic tools for it are tackled. Potential treatments include interleukin 1 (IL-1) receptor antagonists, resolvins and selective glucocorticoid receptor agonists.

SYNERGEN ADVANCES DEVELOPMENT OF POTENTIAL ARTHRITIS TREATMENT BOULDER, Colo., Aug. 1 /PRNewswire/ -- Synergen Inc. (NASDAQ: SYGN) announced today that it expects to begin human clinical trials soon to evaluate [...]

The article presents a study on Novartis' ACZ885 or Ilaris, a drug that blocks an interleukin-1 beta protein that linked to inflammation and to treat gout. The findings of the study were showed at the European Pediatric Rheumatology Congress in Bruges, Belgium, in which one of the investigators of the study Pierre Quartier says that the study recommended ACZ885 as an essential alternative treatment for children with systemic juvenile idiopathic arthritis (SJIA).

Synergen and University of Colorado Synergen Inc. and the University of Colorado Foundation Inc. announced that they have obtained a U.S. patent on the DNA for interleukin-1 inhibitors and methods [...]

Synergen Inc. Synergen Inc. announced that it has received permission from the U.S. Food and Drug Administration to begin testing Antril, its interleukin-1 receptor antagonist, in three new clinical indications. [...]